Finance

Lists
TAK:NYSE
Takeda Pharmaceutical Co Ltd
18,60 US$
-0,46%
(-0,085) 1D
13 ოქტ, 15:35:05 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TAK...
Open
18,73 US$
High
18,82 US$
Low
18,55 US$
Mkt. cap
59,03 მლრდ.
Avg. vol.
2,38 მლნ.
Volume
1,98 მლნ.
Dividend
3,39%
Quarterly dividend
0,16 US$
Ex-dividend date
29 სექ. 2026
52-wk high
19,10 US$
52-wk low
12,99 US$
EPS
-0,33 US$
Beta
-0,06
Shares outstanding
3,20 მლრდ.
No. of employees
47 ათ.
Open
18,73 US$
High
18,82 US$
Low
18,55 US$
Mkt. cap
59,03 მლრდ.
Avg. vol.
2,38 მლნ.
Volume
1,98 მლნ.
Dividend
3,39%
Quarterly dividend
0,16 US$
Ex-dividend date
29 სექ. 2026
52-wk high
19,10 US$
52-wk low
12,99 US$
EPS
-0,33 US$
Beta
-0,06
Shares outstanding
3,20 მლრდ.
No. of employees
47 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
8 საათის წინ
Takeda Pharmaceutical stock trades at 53.16 times earnings
ad-hoc-news.de
ad-hoc-news.de
·
12 საათის წინ
Analysts raised target for Takeda Pharmaceutical stock to JPY 5,800
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOკრისტოფ ვებერი | კრისტოფ ვებერი
Employees47 ათ.
Founded12 ივნ. 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Analyst ratings
Based on 1 analyst giving stock ratings to TAK in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for TAK in the last 3 months
Highest
Current 18,60 US$
42,95 US$ (+130,96%)
Average
42,95 US$ (+130,98%)
Lowest
42,95 US$ (+130,96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Koichi Mamegano
Bank of America Securities
Buy
Maintained
6 800,00 JPY
+36 469%
09/14/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
21,00 US$
+12,9%
06/04/2026
Last report
30 ივლ. 2026
Fiscal period
Q1 2026
77,00 JPY / -
0,00%miss
Revenue / Est. (JPY)
1,22 ტრლ. / 1,15 ტრლ.
+6,12%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,11 ტრლ.
1,19 ტრლ.
1,09 ტრლ.
1,22 ტრლ.
Cost of goods sold
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
406,68 მლრ.
Cost of revenue
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
406,68 მლრ.
Research and development expenses
161,48 მლრ.
175,23 მლრ.
187,96 მლრ.
167,40 მლრ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253,55 მლრ.
282,78 მლრ.
291,96 მლრ.
286,51 მლრ.
Operating expense
562,57 მლრ.
661,30 მლრ.
519,65 მლრ.
612,60 მლრ.
Total operating expenses
942,63 მლრ.
1,06 ტრლ.
972,98 მლრ.
1,02 ტრლ.
Operating income
170,17 მლრ.
129,25 მლრ.
121,56 მლრ.
200,62 მლრ.
Other non operating income
77,96 მლრდ.
-197,22 მლრ.
181,53 მლრ.
-28,14 მლრდ.
EBT including unusual items
28,17 მლრდ.
133,86 მლრ.
-455,02 მლრ.
162,72 მლრ.
EBT excluding unusual items
128,86 მლრ.
114,17 მლრ.
71,49 მლრდ.
161,92 მლრ.
Income tax expense
39,90 მლრდ.
30,13 მლრდ.
-86,62 მლრდ.
49,46 მლრდ.
Effective tax rate
141,64%
22,51%
19,04%
30,40%
Other operating expenses
16,12 მლრდ.
67,13 მლრდ.
-64,27 მლრდ.
53,17 მლრდ.
Net income
-11,80 მლრდ.
103,64 მლრ.
-368,47 მლრ.
113,20 მლრ.
Net profit margin
-1,06%
8,70%
-33,66%
9,28%
Earnings per share
-
-
-
-
Interest and investment income
43,92 მლრდ.
181,35 მლრ.
-
24,61 მლრდ.
Interest expense
-161,10 მლრ.
-
-239,63 მლრ.
-35,70 მლრდ.
Net interest expenses
-117,18 მლრ.
181,35 მლრ.
-239,63 მლრ.
-11,09 მლრდ.
Depreciation and amortization charges
-
-
-
-
EBITDA
355,15 მლრ.
319,89 მლრ.
192,73 მლრ.
363,66 მლრ.
Gain or loss from assets sale
303,00 მლნ.
358,00 მლნ.
1,46 მლრდ.
-6,00 მლრდ.
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები